Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemia
Open Access
- 16 April 2020
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (2), 605-609
- https://doi.org/10.3324/haematol.2019.244186
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapyeLife, 2014
- Functions of flt3 in zebrafish hematopoiesis and its relevance to human acute myeloid leukemiaBlood, 2014
- Crenolanib is a selective type I pan-FLT3 inhibitorProceedings of the National Academy of Sciences of the United States of America, 2014
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Blood, 2009
- FLT-3: a new focus in the understanding of acute leukemiaThe International Journal of Biochemistry & Cell Biology, 2005
- Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412Cancer Cell, 2002
- The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blastsBlood, 2001
- Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.The Journal of Experimental Medicine, 1996
- Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitorsImmunity, 1995
- Expression of Flt3 tyrosine kinase receptor gene in mouse hematopoietic and nervous tissuesDifferentiation, 1995